<DOC>
	<DOCNO>NCT01027949</DOCNO>
	<brief_summary>This study provide , continue provide , UT-15C SR ( treprostinil diethanolamine ) eligible patient pulmonary arterial hypertension complete protocols TDE-PH-202 , TDE-PH-203 , TDE-PH-205 , TDE-PH-301 , TDE-PH-302 , TDE-PH-308 study additional UT-15C SR clinical protocol evaluate subject PAH . The study assess long term safety UT-15C effect continue treatment UT-15C exercise capacity one year treatment .</brief_summary>
	<brief_title>An Open-Label Extension Trial UT-15C SR Subjects With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>This open-label study . Each subject 's visit schedule allow assessment define period exposure UT-15C SR ( 3 , 6 , 12 , 24 36 month total exposure ) . The study continue yearly visit beyond 36 month either UT-15C SR approve appropriate regulatory authority study discontinue sponsor . Therefore , actual date visit determine date subject first receive UT-15C SR ( e.g. , date study drug initiation TDE-PH- 301 , TDE-PH-302 , TDE-PH-308 subject randomize active therapy trial , date UT-15C SR initiation study subject randomize placebo previous control trial ) . Note TDE-PH-202 , TDE-PH-203 , TDE-PH-205 study open-label design therefore follow regimen subject receive UT-15C SR .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Participation study TDEPH202 , TDEPH203 , TDEPH205 , TDEPH301 , TDEPH302 , TDEPH308 additional UT15C SR clinical protocol require . Subjects must complete assessment one study eligible .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>